Achmea Investment Management B.V. boosted its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 11.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 45,228 shares of the medical research company’s stock after acquiring an additional 4,673 shares during the quarter. Achmea Investment Management B.V.’s holdings in Agilent Technologies were worth $2,680,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also modified their holdings of the stock. Advisor Group Inc. raised its position in Agilent Technologies by 0.3% during the second quarter. Advisor Group Inc. now owns 3,959 shares of the medical research company’s stock valued at $235,000 after acquiring an additional 10 shares in the last quarter. Bronfman E.L. Rothschild L.P. raised its position in Agilent Technologies by 0.8% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 4,658 shares of the medical research company’s stock valued at $276,000 after acquiring an additional 35 shares in the last quarter. Veritable L.P. raised its position in Agilent Technologies by 0.4% during the second quarter. Veritable L.P. now owns 10,896 shares of the medical research company’s stock valued at $646,000 after acquiring an additional 40 shares in the last quarter. Park National Corp OH raised its position in Agilent Technologies by 1.1% during the second quarter. Park National Corp OH now owns 4,077 shares of the medical research company’s stock valued at $242,000 after acquiring an additional 43 shares in the last quarter. Finally, Trust Co. of Vermont raised its position in Agilent Technologies by 1.8% during the second quarter. Trust Co. of Vermont now owns 2,793 shares of the medical research company’s stock valued at $166,000 after acquiring an additional 50 shares in the last quarter.
In other Agilent Technologies news, CFO Didier Hirsch sold 1,200 shares of the company’s stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $66.00, for a total value of $79,200.00. Following the transaction, the chief financial officer now directly owns 164,202 shares of the company’s stock, valued at approximately $10,837,332. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michael R. Mcmullen sold 16,492 shares of the company’s stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $65.33, for a total value of $1,077,422.36. Following the completion of the transaction, the chief executive officer now directly owns 211,872 shares in the company, valued at $13,841,597.76. The disclosure for this sale can be found here. Insiders have sold a total of 165,720 shares of company stock worth $10,488,739 over the last three months.
Shares of Agilent Technologies, Inc. (NYSE:A) traded up 0.67% during midday trading on Friday, hitting $67.33. 239,480 shares of the stock traded hands. The company has a market capitalization of $21.67 billion, a PE ratio of 34.72 and a beta of 1.30. The firm’s 50 day moving average price is $65.65 and its 200 day moving average price is $60.29. Agilent Technologies, Inc. has a 12-month low of $42.92 and a 12-month high of $67.82.
Agilent Technologies (NYSE:A) last posted its earnings results on Tuesday, August 15th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.52 by $0.07. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. Agilent Technologies had a return on equity of 16.95% and a net margin of 14.36%. The firm’s revenue was up 6.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.49 EPS. Analysts expect that Agilent Technologies, Inc. will post $2.32 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 25th. Investors of record on Tuesday, October 3rd will be issued a dividend of $0.132 per share. This represents a $0.53 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date of this dividend is Monday, October 2nd. Agilent Technologies’s payout ratio is presently 27.32%.
Several equities analysts have commented on the company. Robert W. Baird reiterated a “buy” rating and set a $70.00 price target on shares of Agilent Technologies in a report on Friday. BidaskClub downgraded Agilent Technologies from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 12th. Janney Montgomery Scott increased their price target on Agilent Technologies from $65.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday, August 16th. J P Morgan Chase & Co reiterated an “overweight” rating and set a $70.00 price target on shares of Agilent Technologies in a report on Wednesday, August 16th. Finally, Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and set a $68.00 price target on shares of Agilent Technologies in a report on Tuesday, September 26th. Four research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $65.65.
COPYRIGHT VIOLATION WARNING: “Achmea Investment Management B.V. Acquires 4,673 Shares of Agilent Technologies, Inc. (A)” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.com-unik.info/2017/10/20/achmea-investment-management-b-v-acquires-4673-shares-of-agilent-technologies-inc-a.html.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
What are top analysts saying about Agilent Technologies Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Agilent Technologies Inc. and related companies.